Selank Peptide Reduced Anxiety in Rats with Parkinson's-like Brain Damage | Research

The takeaway

The peptide Selank reduced anxiety in rats with Parkinson's-like dopamine neuron destruction, suggesting its anti-anxiety mechanism works independently of the brain's dopamine system.

Anxiety reduced despite DA neuron loss
Selank's anxiolytic effect persisted in rats with substantia nigra damage, suggesting a dopamine-independent mechanism

What the researchers found

In rats with chemically induced Parkinson's-like symptoms, the peptide Selank (an analog of taftsin) reduced anxiety levels in the elevated plus maze test. Neither Selank nor Semax (an ACTH 4-10 fragment analog) affected motor activity or passive defensive behavior in the parkinsonian rats.

Notably, Selank's anti-anxiety effect persisted even after toxic damage to the substantia nigra — the brain region destroyed in Parkinson's disease. This suggests Selank's anxiolytic mechanism operates independently of the dopaminergic neurons lost in parkinsonism, consistent with its previously demonstrated effects in healthy rodents under stress.

Why it matters

Parkinson's disease is primarily known for its motor symptoms, but anxiety and other neuropsychiatric symptoms affect up to 40% of PD patients and significantly reduce quality of life. Most anti-anxiety medications carry risks for PD patients. Finding that Selank's anti-anxiety effect survives even when dopamine neurons are destroyed suggests it could address non-motor PD symptoms through a separate mechanism.

The numbers in context

6-OHDA lesion model · Elevated cross-shaped maze test · Selank reduced anxiety · No motor activity changes with either peptide · Semax (ACTH 4-10 analog) and Selank (taftsin analog) tested

How the study worked

Researchers induced Parkinson's-like neurodegeneration in male rats using 6-hydroxydopamine (6-OHDA), which selectively destroys dopaminergic neurons in the substantia nigra. Rats were then treated with either Semax or Selank peptides. Behavior was assessed using the elevated plus maze (a standard test for anxiety) and passive defensive behavior paradigms.

Who was studied

Male rats with 6-OHDA-induced parkinsonism

What this study cannot tell us

The 6-OHDA model mimics dopamine neuron loss but doesn't replicate the full complexity of human Parkinson's disease (which involves alpha-synuclein pathology and multiple neurotransmitter systems). The abstract doesn't report sample sizes, specific dosages, treatment duration, or statistical values. Published in a Russian Academy of Sciences proceedings journal with a brief format.

How to read the evidence

This is a preliminary animal study published as a brief communication in a Russian Academy of Sciences journal. While the finding is interesting, the short format means limited detail on methods, statistics, and controls.

When this study was published

Published in 2017, this study adds to the body of Selank research from Russian institutions. The peptide remains primarily available in Russia and is not FDA-approved, so this represents ongoing preclinical investigation rather than translational work toward Western approval.

The bigger picture

Semax and Selank are Russian-developed synthetic peptides with a long history of use in Russia for cognitive and anxiolytic applications, though they lack approval in Western countries. This study extends Selank research into neurodegenerative disease, suggesting its anxiolytic mechanism is robust enough to function even when major brain circuits are damaged. It also highlights the growing recognition that non-motor symptoms of Parkinson's disease deserve targeted treatment strategies.

Questions still open

Through which neurotransmitter systems does Selank exert its anti-anxiety effect if not through dopamine pathways?
Would Selank reduce anxiety in human Parkinson's disease patients, where multiple neurotransmitter systems are affected beyond just dopamine?
Could combining Selank with standard PD motor treatments address both motor and psychiatric symptoms simultaneously?

Common questions

What are Semax and Selank?

Semax and Selank are synthetic peptides developed in Russia. Semax is based on a fragment of ACTH (a stress hormone) and is used for cognitive enhancement. Selank is based on taftsin, an immune-modulating peptide, and is primarily used for anxiety. Both are available as nasal sprays in Russia but are not approved in Western countries.

Why is anxiety important in Parkinson's disease research?

While Parkinson's is best known for tremors and movement problems, up to 40% of patients also suffer from anxiety, which significantly impacts quality of life. Current anti-anxiety medications can interact poorly with PD drugs or worsen motor symptoms. Finding treatments that target anxiety through non-dopamine pathways could help these patients.

Read the original research

Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.

Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 474(1), 106-109

View on PubMed ↗Publisher’s paper ↗

Citation

Slominsky, P A; Shadrina, M I; Kolomin, T A; Stavrovskaya, A V; Filatova, E V; Andreeva, L A; Illarioshkin, S N; Myasoedov, N F. (2017). Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism.. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 474(1), 106-109. https://doi.org/10.1134/S0012496617030048